Cystic hygroma is a rare congenital malformation caused by abnormal development of lymphatic vessels. It is usually diagnosed during pregnancy, often in the second trimester. The condition is characterized by a fluid-filled sac that is located in the neck, chest, or abdomen. Cystic hygroma can cause a variety of symptoms, including difficulty breathing, respiratory distress, and even cardiac problems. Ultrasound is the primary imaging modality used to diagnose cystic hygroma, as it can provide detailed images of the affected area. In this article, we will discuss the ultrasound features of cystic hygroma, as well as the implications for patient care.
Cystic hygroma is a rare congenital malformation caused by abnormal development of lymphatic vessels. It is usually diagnosed during pregnancy, often in the second trimester. The condition is characterized by a fluid-filled sac that is located in the neck, chest, or abdomen. Cystic hygroma can cause a variety of symptoms, including difficulty breathing, respiratory distress, and even cardiac problems.
Ultrasound is the primary imaging modality used to diagnose cystic hygroma, as it can provide detailed images of the affected area. On ultrasound, cystic hygroma appears as a large, fluid-filled cyst with a thin wall. The cyst may be located in the neck, chest, or abdomen. It may also be associated with other anomalies, such as cardiac defects or skeletal abnormalities. The size of the cyst can vary, but it is typically larger than 5 cm in diameter. It may also have septations, which are thin walls that divide the cyst into smaller compartments. The cyst may also contain debris, which may appear as echogenic material on ultrasound.
The diagnosis of cystic hygroma has important implications for patient care. If the condition is detected during pregnancy, the patient should be closely monitored for any signs of respiratory distress or cardiac problems. In addition, the patient should be referred to a specialist for further evaluation and management. If cystic hygroma is detected after birth, the patient should be referred to a specialist for further evaluation and management. Treatment may include surgical removal of the cyst or drainage of the cyst with a needle. In some cases, medications may be used to reduce the size of the cyst.
Cystic hygroma is a rare congenital malformation caused by abnormal development of lymphatic vessels. Ultrasound is the primary imaging modality used to diagnose cystic hygroma, as it can provide detailed images of the affected area. The diagnosis of cystic hygroma has important implications for patient care, and patients should be referred to a specialist for further evaluation and management. Treatment may include surgical removal of the cyst or drainage of the cyst with a needle, as well as medications to reduce the size of the cyst.
1.
Glioblastoma treatment breakthrough shows promise
2.
MET Inhibitor Increases Osimertinib Activity in EGFR+ Advanced NSCLC
3.
Study suggests exercise could reduce breast cancer recurrence
4.
Off-the-Shelf Drug Matches CAR-T Effects in Refractory Lupus
5.
Daily physical activity, even at light intensities, linked to lower cancer risk
1.
Lentigo Maligna Melanoma: Everything You Need To Know about This Skin Cancer
2.
Pediatric Oncology at the Cutting Edge: From Early Diagnosis to Lifesaving Therapies
3.
Advancements in Survival Mechanisms and Prognostic Determinants in Acute Myeloid Leukemia
4.
HPV Infection Review: Epidemiology, Risks, and Therapeutic Advances for Clinicians
5.
Case Study: Diagnostic and Therapeutic Challenges in Aplastic Anemia Mimicking Hypoplastic Myelodysplastic Syndrome
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
The Landscape of First-Line Treatment for Urothelial Carcinoma- The Conclusion
2.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Important Points to Know
3.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VI
4.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias- The Summary
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VII
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation